Nov 04 2021 Relmada Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 11, 2021 View
Oct 29 2021 Relmada Therapeutics to Present Data at the Neuroscience Education Institute Congress View
Oct 04 2021 Relmada Therapeutics Provides Regulatory and Development Updates on Ongoing Late-Stage Clinical Program for REL-1017 for Treatment of Major Depressive Disorder View
Sep 17 2021 Relmada Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit View
Sep 03 2021 Relmada Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference View
Aug 10 2021 Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results View
Aug 05 2021 Relmada Therapeutics to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 10, 2021 View
Jul 27 2021 Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential View
Jul 20 2021 Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC View
Jun 15 2021 Relmada Therapeutics to Present Data at the College on Problems of Drug Dependence 83rd Annual Scientific Meeting View
